Zimmer Biomet (NYSE:ZBH – Get Free Report) will issue its quarterly earnings data before the market opens on Wednesday, August 7th. Analysts expect the company to announce earnings of $1.98 per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.
Zimmer Biomet Trading Down 3.0 %
Shares of ZBH opened at $107.04 on Tuesday. The business has a 50-day moving average of $109.75 and a 200 day moving average of $119.09. Zimmer Biomet has a fifty-two week low of $102.00 and a fifty-two week high of $133.90. The firm has a market cap of $22.02 billion, a P/E ratio of 23.17, a price-to-earnings-growth ratio of 1.99 and a beta of 1.01. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.80 and a current ratio of 1.66.
Zimmer Biomet Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, July 31st. Investors of record on Wednesday, June 26th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.90%. The ex-dividend date was Wednesday, June 26th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 20.78%.
Analyst Upgrades and Downgrades
View Our Latest Research Report on Zimmer Biomet
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
See Also
- Five stocks we like better than Zimmer Biomet
- What Are Dividend Champions? How to Invest in the Champions
- From Tokyo to Wall Street: Japan’s Market Impact on U.S. Stocks
- What are earnings reports?
- Arm Holdings: Does the 42% Drop Signal an AI Buying Opportunity?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Texas Roadhouse Stampedes On EPS Beat as Comp Sales Surge 9.3%
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.